RespireRx Secures $1.5M NIH Grant to Advance Novel Epilepsy Treatment KRM-II-81 Toward Clinical Trials
核心洞察
RespireRx Pharmaceuticals (搜索) received a $1.5 million NIH/NINDS (搜索) SBIR grant to complete preclinical toxicology studies for KRM-II-81, a novel GABAkine compound for epilepsy (搜索) treatment.
KRM-II-81 demonstrated high anti-seizure activity across 34 preclinical models without developing tolerance or resistance, addressing a major limitation of current epilepsy (搜索) medications.
The compound showed analgesic efficacy comparable to standard pain (搜索) medications without producing sedation, dependence, or abuse liability associated with opioids.
RespireRx Pharmaceuticals (搜索) has secured a significant $1,499,869 grant from the National Institutes of Health (NIH) and National Institute of Neurological Disorders and Stroke (NINDS (搜索)) to advance its lead epilepsy (搜索) treatment candidate toward clinical trials. The Small Business Innovation Research (SBIR) award, announced on September 23, 2025, will fund preclinical toxicology studies necessary to support an investigational new drug (IND) application for KRM-II-81.
Novel GABAkine Shows Promise Against Treatment-Resistant Epilepsy
KRM-II-81 represents a new class of compounds called GABAkines that selectively amplify inhibitory neurotransmission at specific GABAA receptor subtypes. This targeted mechanism produces what the company describes as "a unique efficacy profile with reduced side effects" compared to conventional epilepsy (搜索) medications.
The compound has demonstrated remarkable anti-seizure activity across 34 different preclinical models, including treatment-resistant and pharmaco-resistant animal models. Critically, KRM-II-81 maintained its effectiveness without developing tolerance or resistance—a major advantage over current epilepsy (搜索) treatments that can lose efficacy with chronic use.
"Pharmaco-resistance occurs when medications that once controlled seizures lose efficacy because of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures," the company noted in its announcement.
Translational Evidence from Human Brain Tissue
Supporting its clinical potential, translational studies have shown KRM-II-81's ability to dramatically reduce epileptiform electrical activity when administered to brain slices from treatment-resistant epileptic patients who underwent surgery. These three studies provide compelling evidence that the compound's preclinical efficacy may translate to human patients.
Dual Indication Potential: Pain Management Without Opioid Risks
Beyond epilepsy (搜索), KRM-II-81 has shown significant analgesic properties in seven preclinical pain (搜索) studies. The compound's pain-relieving efficacy was comparable to or greater than commonly used analgesics, while notably avoiding the problematic side effects associated with opioid medications.
"KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression (搜索) or behavioral changes indicative of abuse liability, which are produced by opioid analgesics that are at the heart of the opioid epidemic," according to the company.
The NINDS (搜索) Division of Translational Research is currently profiling KRM-II-81's analgesic and side-effect characteristics, indicating institutional interest in the compound's pain (搜索) management potential.
Strategic Partnership Restructured
Concurrent with the grant announcement, RespireRx amended its patent license agreement with the University of Wisconsin-Milwaukee Research Foundation (搜索). The updated agreement, executed through RespireRx's EndeavourRx LLC (搜索) subsidiary, includes revised regulatory milestone payments, updated royalty structures, and streamlined intellectual property management.
The GABAkines were originally developed in the laboratory of Dr. James Cook, UWM Distinguished Professor Emeritus, who pioneered their selective targeting of GABAA receptor subtypes.
Funding and Development Timeline
The two-year NIH grant provides $1.5 million of the $3 million total requested for the project, running from September 23, 2025, through August 31, 2027. The funding will specifically support preclinical toxicology studies and related regulatory preparation activities required for IND submission.
RespireRx's broader pipeline includes additional neuromodulator compounds targeting neurological and psychiatric disorders, including ADHD (搜索), spinal cord injury recovery, and obstructive sleep apnea (搜索) through its subsidiary companies EndeavourRx LLC (搜索) and ResolutionRx Ltd (搜索).
The company's approach focuses on addressing conditions "affecting millions of people, but for which there are few or poor treatment options," positioning KRM-II-81 as a potential breakthrough therapy for both epilepsy (搜索) and pain (搜索) management markets.